Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Recruiting Not applicable

Mediating Role of Myokines in the Dialogue Between Muscle and Bone Tissue in a Population of Healthy Women Aged 20-89 Years

NCT06683222 · tracked via the Priya Life Science France tracker
Phase
Not applicable
Started
2024-11-06
Last updated
2024-11-29

Condition(s) studied

Bone Density

Investigational drug(s) / intervention(s)

Blood sampleSaliva sampleGrip testMicroFET2® maximum isometric force testMaximum isometric knee extension bench test.The SPPB (Short Physical Performance Battery)The 6-minute walking test.Segmental impedancemetry examination.Indirect calorimetry test.Fardellone's questionnaireONAPS questionnaireDietary intake.questionnaire

Blood sample: 36 ml of blood in 3 x 7 ml dry tubes, 1 x 5 ml EDTA tube, 1 x 5 ml heparinized tube, 1 x 5 ml anti-protease tube)

Saliva sample: 5 ml of saliva will be taken.

Grip test: The grip strength of the dominant arm will be measured with the participant in a standing position, with the arm close to the body and the elbow at 90◦ flexion, while the non-dominant arm will be positioned alongside the body. Three measurements will be taken for the dominant hand, and the mean value will be calculated and used for analysis. One minute is allowed between each repetition, to avoid muscle fatigue. Dynamometer quality control is ensured by regularly checking known resistance values.

MicroFET2® maximum isometric force test: The microFET2 device is used to test isometric force. The microFET2 dynamometer is battery-powered and ergonomically designed to fit in the palm of the hand. The system is microprocessor-controlled to provide accurate, repeatable muscle force readings. The microFET Clinical software automatically performs calculations and validity tests, and allows graphs to be generated from the data, enabling reports of different patient tests to be compared

Maximum isometric knee extension bench test.: The maximal isometric knee extension strength test on a specially-adapted strength bench consists in performing 3 maximal contractions with 1 minute's rest between each test.

The SPPB (Short Physical Performance Battery): Battery of tests comprising a balance test, a walking speed test and a chair-lift test

The 6-minute walking test.: Muscular function will be determined by the 6-minute walk test to assess aerobic endurance. Participants will be asked to walk for 6 min as fast as possible on a shuttle track. The distance (m) covered in 6 min will be measured. Walking speed (m/s) will be calculated as the distance (m) covered in 6 min. A walking speed \<0.8 m/s has been defined as a low value.

Segmental impedancemetry examination.: Segmental impedancemetry involves measuring body composition using the body's resistance to the passage of a low-intensity electric current. This test is harmless to the body.

Indirect calorimetry test.: An Indirect calorimetry is the standard method for measuring energy expenditure at rest. It is based on the principle that the human body burns nutrients using O2 and producing CO2.

Fardellone's questionnaire: Completion of a questionnaires on calcium intake (Fardellone)

ONAPS questionnaire: The ONAPS questionnaire contains questions on physical activity and sedentariness

Dietary intake.questionnaire: The dietary intake questionnaire contains questions regarding the person's eating habits - how many meals a day, where they eat, whether they eat alone, what foods they eat/drink and whether they are following a particular diet and, if so, the reasons why.

Study summary

The main hypothesis is that muscle acts on bone tissue via the secretion of myokines (myostatin, follistatin, irisin). This is based on previous results showing that muscle mass in different patient populations with very different body mass indexes (anorexic or obese patients) is significantly and independently associated with bone mineral density.

Eligibility

Sex
FEMALE
Min age
20 Years
Max age
89 Years
Healthy volunteers
Accepted
Inclusion Criteria: * Self-reported Caucasian ethnicity (Europe, Middle East, North Africa) only as there is a difference in BMD by ethnicity. * Person affiliated with or benefiting from a social security scheme. * Free, informed consent signed by the participant and the investigator (at the latest on the day of inclusion and before any examination required by the research). Exclusion Criteria: * Fragility fracture defined as a spontaneous or low-kinetic fracture (≤ one fall from height). * Early menopause (\< 40 years), hysterectomy (complete \< 40 years), primary amenorrhea (absence of menstruation before 15 years), current amenorrhea of more than 3 months without contraceptive if the patient is less than 40 years old. * Patients on treatments: prolonged corticosteroid therapy \> 3 months or \> 1 g (cumulative dose). * Immobilization of more than 3 months, less than 12 months old. * Hip fracture in a first-degree relative. Patients with any of the following pathologies affecting bone, muscle or adipose tissue: * Inflammatory bowel disease (IBD: Crohn's disease, ulcerative colitis) and untreated celiac disease. * Renal insufficiency on dialysis or patients with nephrology follow-up. * Known hypercalciuria. * Osteomalacia, rickets, osteogenesis imperfecta. * Osteopathy (Paget's disease, osteopetrosis, etc.). * Chronic inflammatory rheumatism. * Hemopathy, neoplasia. * Hepatic insufficiency or chronic hepatitis. * Endocrinopathy: diabetes, dysthyroidism, hypogonadism, hypercorticism, untreated acromegaly. * Anorexia nervosa. * Hyperparathyroidism (even controlled). * History of digestive surgery (bariatric, gastrectomy, digestive resection other than appendectomy, etc.). * History of organ transplantation. * Chronic infectious disease (HIV, etc.). * Weight loss of more than 10 kg within 6 months. * Paresis, marked lameness or unloading of a limb, or prolonged immobilization of more than one month in the last 12 months. * Patients on treatments that may affect bone mass or body composition: * Biphosphonates (Alendronate (Fosamax® and generics), Risedronate (Actonel® and generics), Zoledronate (Aclasta® and generics). * Teriparatide (Forsteo®). * Denosumab (Prolia®) * Selective estrogen receptor modulators (Clomifene, Tamoxifene, Toremifene, Raloxifene). * Anabolic steroids. * Strontium ranelate. * Carbamazepine. * Phenobarbital. * Immunosuppressants. * Patients on anti-epileptics. * Patients with any of the following abnormalities in the measurement area: * Major deformities of the wrist, hip or vertebrae. * Compression of vertebral bodies, cementoplasty. * Prosthesis, implant (breast, buttock, etc.), foreign body. * Hip paraosteoarthropathy. * Injection of radiological contrast medium, barium enema, nuclear medicine examination within 10 days. * Intensive sport (more than 10 h/week). * Extreme BMI (BMI \< 18, BMI \> 35 kg/m²). * Loss of autonomy. * People with neurodegenerative disorders affecting their ability to give consent. * Pregnant, parturient or breast-feeding women. * Participation in an interventional study involving a drug or medical device or a category 1 RIPH within 3 months prior to inclusion.

Primary outcome measure(s)

  • Myostatin — Baseline
    Plasma concentration of myostatin will be measured in pg/ml by Enzyme-Linked Immuno Sorbent Assay
  • Follistatin — Baseline
    Plasma concentration of follistatin will be measured in pg/ml by Enzyme-Linked Immuno Sorbent Assay
  • Irisin — Baseline
    Plasma concentration of irisin will be measured in pg/ml by Enzyme-Linked Immuno Sorbent Assay
  • Bone Mineral Density — Baseline
    Bone densitometry using X-ray absorptiometry (DXA) measured in g/cm²
  • Lean body mass — Baseline
    Impedencemetry, measured in Kg

Trial sites (2)

FacilityCityRegionStatus
C.H.R.U. Lapeyronie Montpellier France Recruiting
Chu Nimes Nîmes France Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06683222 on ClinicalTrials.gov ↗ ← All trials in France